PANCREATIC DUCTAL ADENOCARCINOMA

This early-stage trial tests a new type of immunotherapy where a patient's own T cells are genetically engineered to recognize and attack cancer cells with a specific KRAS G12D mutation. The study includes adults with advanced lung, colorectal, pancreatic, or endometrial cancers …

This study is testing a new biologic drug called sacituzumab tirumotecan (MK-2870), alone or with chemotherapy, in people with advanced colorectal, pancreatic, or biliary tract cancers that cannot be removed by surgery. The main goals are to check safety and see if tumors shrink.…

This early-stage trial tests a new drug called YL211 in 155 people with advanced solid tumors who have no standard treatment options left. The study has three parts: first, finding a safe dose; then, confirming that dose; and finally, testing how well it works. The main goals are…

This early-stage trial is testing whether adding an experimental cancer vaccine (ELI-002 7P) and an immunotherapy drug (tislelizumab) to standard chemotherapy (mFOLFIRINOX) is safe and effective for people with a specific type of pancreatic cancer that has a KRAS mutation. The st…

This study looks at whether removing the entire pancreas is better than removing just part of it for people with certain cancers in the head of the pancreas who are at high risk of complications. The main goal is to see if total removal helps patients live longer without hurting …

This phase 2 trial is testing whether giving two immunotherapy drugs, durvalumab and oleclumab, before surgery can boost the immune system's attack on pancreatic cancer. The study involves people with resectable pancreatic ductal adenocarcinoma (PDAC) who will receive the drugs i…

This Phase 3 trial tests whether adding an experimental oral drug called atebimetinib to a modified chemotherapy regimen helps people with metastatic pancreatic cancer live longer. About 510 adults who have not had prior treatment will receive either the new combination or standa…

This early-phase study tests a new drug, LY3962673, in people with advanced solid tumors that have a specific KRAS G12D mutation, including pancreatic, lung, and colorectal cancers. The main goals are to check safety and see if the drug shrinks tumors, given alone or with chemoth…

This study tests an experimental oral drug called S241656 (BDTX-4933) in people with advanced solid tumors that have certain genetic changes (KRAS, BRAF, or other RAS/MAPK mutations). The trial has two parts: first, finding a safe dose, then testing how well it works alone or wit…

This early-stage trial is testing a new radioactive drug (177Lu-DFC413) to see if it is safe and can shrink tumors in people with advanced solid cancers like pancreatic, lung, breast, colorectal, and sarcoma. About 180 adults whose cancer has progressed after standard treatments …

This study tests a new drug called AZD4360 in adults with advanced solid tumours that have a specific marker (CLDN18.2). The drug is an antibody-drug conjugate designed to deliver a toxic payload directly to cancer cells. The trial aims to find the safest dose and see if it shrin…

This early-phase study tests a new combination treatment for people with advanced pancreatic cancer that has spread or cannot be removed by surgery. The treatment uses specially engineered immune cells (NK cells) from donated cord blood, given through a belly infusion and a vein,…

This early-stage trial tests a new drug called M7437 in people with advanced solid tumors that have not responded to standard treatments. M7437 is an antibody-drug conjugate designed to deliver chemotherapy directly to cancer cells that have a specific marker (Ly6E). The study ai…

This Phase 2 trial tests a combination of two immunotherapy drugs, odetiglucan and mitazalimab, as a maintenance treatment for people with unresectable pancreatic cancer that has not worsened after 4-8 months of standard chemotherapy. The study will enroll 100 adults and measure …

This phase 2 trial tests whether giving a powerful chemotherapy regimen called NALIRIFOX along with targeted radiation and the drug capecitabine can shrink pancreatic tumors enough to allow successful surgery. The study enrolls 60 people with borderline resectable or locally adva…

This phase 3 trial tests whether adding radiotherapy to standard chemotherapy after pancreatic cancer surgery can prevent the cancer from coming back. It enrolls 288 high-risk patients who have had surgery but still have factors like positive margins or lymph node involvement. Pa…

This study tests whether adding the drug BMS-986504 to standard chemotherapy can help control pancreatic cancer in people with a specific genetic change (MTAP deletion). About 60 adults with this type of pancreatic cancer will receive the combination before and after surgery or w…

This study tests an experimental drug called BLU-924 (SAR449336) in people with advanced pancreatic, lung, or colorectal cancers that have specific KRAS mutations. The drug is designed to block the cancer-driving KRAS protein. The trial will enroll about 265 participants to evalu…

This study tests a new drug that delivers a tiny dose of radiation directly to cancer cells that have a specific marker called FAP. The trial involves 112 adults with advanced cancers of the pancreas, stomach, esophagus, colon, ovary, head/neck, sarcoma, or mesothelioma. First, a…

This early-stage trial tests a new drug called PHN-012 in people with advanced colon, pancreatic, or lung cancer that has stopped responding to standard treatments. The drug is an antibody-drug conjugate, designed to deliver a powerful cancer-killing agent directly to tumor cells…

This early-phase trial is testing a new type of cell therapy for people with advanced pancreatic cancer that has spread or cannot be removed by surgery. The treatment uses specially engineered natural killer (NK) cells that target two proteins found on cancer cells. Up to 42 part…

This phase 2 study tests a new drug called IBI343 combined with two chemotherapy drugs (gemcitabine and nab-paclitaxel) in people with advanced stomach, gastroesophageal junction, or pancreatic cancers that have a specific protein (CLDN18.2). The goal is to see if the combination…

This early-stage trial is testing an experimental drug called BMS-986488, alone or combined with other cancer drugs, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and find the right dose. About 437 adults w…

This early-phase study tests a new drug called CT3001 in people with advanced solid tumors (like colorectal or pancreatic cancer) that have stopped responding to standard treatments. The study has two parts: first, finding a safe dose of CT3001 alone, then testing it combined wit…

This early-phase trial tests an experimental drug called ASP2138 in 25 adults with resectable pancreatic cancer whose tumors have a specific protein (CLDN18.2). Participants receive ASP2138 two weeks before surgery, then standard chemotherapy after surgery. The main goal is to ch…

This early-phase trial tests a drug called TTI-101 combined with a precise type of radiation (SBRT) in 18 people with pancreatic cancer that is borderline resectable or locally advanced. The goal is to see if the combination is safe and can improve how long patients live without …

This phase 2 trial is testing a combination of four drugs (HRS-4642, gemcitabine, albumin-bound paclitaxel, and adebrelimab) as treatment for pancreatic cancer before and after surgery. The goal is to see if this approach is safe and effective at shrinking tumors and improving su…

This phase 2 trial is testing whether adding the experimental drug HRS-4642 to standard chemotherapy (gemcitabine and albumin-bound paclitaxel) can help shrink pancreatic tumors before surgery and prevent recurrence afterward. About 30 adults with resectable or borderline resecta…

This early-phase study tests a new drug called DSB2455 in adults with advanced cancers (breast, ovarian, prostate, pancreatic, or brain metastases) that have a specific DNA repair problem. The main goals are to check safety and see if the drug shrinks tumors. About 180 participan…

This early-stage trial is testing a new drug that delivers a tiny amount of radiation directly to cancer cells. It is for people with advanced solid tumors (like lung, colon, or pancreatic cancer) that have not responded to standard treatments. The study will check if the drug is…

This study tests whether adding a targeted drug called panitumumab to standard chemotherapy helps people with a specific type of advanced pancreatic cancer (KRAS wild-type) live longer. About 94 adults whose cancer has spread or can't be removed will be randomly assigned to get c…

This early-stage trial tests an experimental drug called KQB548 in people with advanced solid tumors (like pancreatic, colorectal, or lung cancer) that have a specific KRAS G12D mutation. The main goals are to find a safe dose and see if the drug can shrink tumors. About 78 parti…

This study tests a new experimental drug called mavrostobart (PT199) in people with advanced solid tumors, specifically non-small cell lung cancer and pancreatic cancer. The drug is given alone or combined with other cancer treatments. The goal is to find the safest dose and see …

This early-phase trial tests a new drug called PTM-101 given alongside standard chemotherapy for people with pancreatic cancer that is either borderline resectable or locally advanced (meaning it has not spread far but is hard to remove surgically). The goal is to see if adding P…

This expanded access program offers ELI-002 7P, an immunotherapy, to pancreatic cancer patients with specific KRAS or NRAS gene mutations who have had their tumor removed but are at high risk of the cancer coming back. The treatment aims to stimulate the immune system to target a…

This early-phase study tests a new treatment for people with advanced pancreatic cancer that has spread and has a specific mutation called KRAS G12D. The treatment uses tiny particles called exosomes to deliver a molecule that blocks the mutated gene. The goal is to find the best…

This study tests a new treatment called KSQ-004EX for people with advanced solid tumors that have not responded to standard therapies. The treatment uses a patient's own immune cells (tumor infiltrating lymphocytes) that are genetically modified to be more powerful against cancer…

This early-phase trial is testing a new drug called ASP5834 in people with advanced solid tumors that have certain changes in the KRAS gene. The study will first find a safe dose of ASP5834 given alone or with another drug (panitumumab) in people with colorectal cancer. Up to 364…

This study tests a new drug called BNT329 in people with advanced solid tumors that have a specific marker (CA19-9). The main goals are to check safety and find the best dose. About 245 participants will take part. The drug works by targeting cancer cells and may help control tum…

This early-stage trial is testing a new drug called IBI3028 in people with advanced solid tumors that cannot be removed by surgery or have spread. The drug works by attaching to two proteins (EGFR and c-Met) found on some cancer cells and delivering two anti-cancer agents directl…

This early-phase study tests a new drug called IBI343 in people with advanced solid tumors that cannot be removed by surgery or have spread. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. About 470 participants will take part in mul…

This study tests a drug called tegavivint in children, teens, and young adults whose solid tumors have come back or stopped responding to treatment. The goal is to find the safest dose and see if it can shrink tumors by blocking a key growth signal inside cancer cells. About 147 …

This early-stage trial is testing a new type of targeted radiation therapy for people with advanced pancreatic, lung, breast, or colorectal cancers. The treatment uses a radioactive drug that seeks out cancer cells to deliver radiation directly, aiming to kill them while sparing …

This study tests two experimental drugs, elironrasib and daraxonrasib, given alone or together, in people with advanced solid tumors that have a specific KRAS G12C mutation. The goal is to see if the drugs are safe and can shrink or control the cancer. About 534 adults with lung,…

This study tests a new daily pill, VS-7375, in people with advanced solid tumors (like pancreatic, lung, or colorectal cancer) that have a specific KRAS G12D mutation. The goal is to see if the drug is safe and can shrink tumors when used alone or with other cancer treatments. Ab…

This study tests a drug called 177Lu-FAP-2286, which delivers radiation directly to cancer cells. It is for people with advanced solid tumors (like pancreatic, lung, or breast cancer) that have a specific protein called FAP. The trial has two parts: Phase 1 finds the safest dose,…

This early-phase study tests an experimental drug called PF-08046050 in adults with advanced solid tumors (like lung, colon, or stomach cancer) that have come back or not improved with standard treatments. The drug is designed to stick to cancer cells and kill them. The main goal…

This study tests a new drug called JPI-547, taken as a pill, together with standard chemotherapy for people with advanced pancreatic cancer that cannot be removed by surgery. The goal is to find the safest dose and see if the combination helps shrink tumors or slow the disease. A…

This early-phase trial is testing a new antibody drug called ZM008, first by itself and then together with another drug (toripalimab), in people with advanced solid tumors like lung, head and neck, and pancreatic cancers. The study aims to find a safe dose and see if the combinat…

This early study tests a device called Suizenji that uses focused ultrasound waves to heat and destroy pancreatic cancer cells from outside the body. It is for 10 adults with advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if the treatment is safe…

This study is testing several new experimental drugs (RAS(ON) inhibitors) combined with standard chemotherapy or other targeted therapies in people with advanced colorectal or pancreatic cancer that has spread. The goal is to see if these combinations are safe and can shrink tumo…

This early-phase trial tests a new drug called VVD-159642, which targets specific cancer-driving proteins. It is given alone or with other drugs (sotorasib or trametinib) to people with advanced solid tumors that have certain genetic changes. The main goals are to check safety, f…

This early-phase trial tests an experimental drug called BI 765049 in adults with advanced colorectal, stomach, or pancreatic cancer that cannot be removed by surgery or has spread. The main goal is to find the highest dose people can tolerate and to see if the drug helps the imm…

This phase 2 trial tests a new approach for people with metastatic pancreatic cancer: alternating two standard chemotherapy regimens every month instead of using just one. The goal is to see if this switching strategy can keep the cancer from growing for at least 6 months. About …

This study tests an experimental drug called ART0380, taken as a pill, in people with advanced or metastatic solid tumors (cancers that have spread). The drug targets a protein that helps cancer cells repair their DNA. Researchers want to find the safest dose when given alone or …

This study tests whether adding a medical glue (Glubran 2) to the surgical connection in the pancreas can prevent a serious complication called pancreatic fistula, which is a leak of digestive fluids. About 100 adults undergoing pancreas removal for cancer will be randomly assign…

This study tests a new drug called ABSK141 in people with advanced solid tumors that have a specific gene change called KRAS G12D. The goal is to find a safe dose and see if the drug can shrink tumors. About 401 adults with cancers like colorectal, lung, or pancreatic cancer will…

This study tests whether combining two drugs, AK130 and AK112, can help control advanced pancreatic cancer. About 160 adults whose cancer has worsened after up to two prior treatments will receive the combination or AK112 alone. The goal is to see if the treatment shrinks tumors …

This phase 2 trial tests whether adding drugs that block the tumor's immune-evasion pathways to standard radiation and immunotherapy can boost the body's immune attack on pancreatic cancer before surgery. About 60 patients with advanced pancreatic cancer who are candidates for su…

This study tests an experimental drug called AZD5863 in adults with advanced stomach, gastro-esophageal junction, pancreatic, or esophageal cancers that have spread. The drug is a bispecific antibody designed to bring immune cells close to cancer cells to attack them. The main go…

This study tests a new drug called ARV-806 in adults with advanced solid tumors that have a specific KRAS G12D mutation. The drug aims to break down the mutated protein that helps tumors grow. The trial has two parts: first, finding a safe dose in small groups, then testing that …

This study tests a new drug called AZD0901, alone or with other cancer treatments, in people with advanced solid tumors that have a specific protein called CLDN18.2. The goal is to see if the drug is safe and can shrink tumors. About 224 adults with stomach, pancreatic, or bile d…

This early-stage trial is testing a combination of two chemotherapy drugs (melphalan and BCNU) plus vitamins B12b and C, followed by an infusion of the patient's own stem cells. The goal is to see if this approach is safe for people with metastatic pancreatic or breast cancer, es…

This early-phase trial is testing a new drug called OMTX705, which targets a protein on cancer cells, combined with standard chemotherapy and an immunotherapy for people with advanced pancreatic cancer that has spread. The study will enroll 69 participants to first find the safes…

This study compares two types of Whipple surgery for people with pancreatic or nearby cancers: the traditional open surgery and a newer keyhole (laparoscopic) approach. About 90 adults with resectable tumors will be randomly assigned to one of the two procedures. The goal is to s…

This early-phase study tests a new treatment called IX001 TCR-T for people with advanced pancreatic cancer that has a specific genetic change (KRAS G12V). The treatment uses the patient's own immune cells, which are modified in a lab to better recognize and attack the cancer. The…

This early-stage trial is testing a new drug called DR-0202, a bispecific antibody, in people with advanced solid tumors (such as breast, lung, and pancreatic cancers) that have not responded to at least two prior treatments. The study aims to find a safe dose and see if the drug…

This trial tests a personalized cell therapy for advanced pancreatic cancer. Patients receive their own immune cells that have been engineered to recognize and attack cancer cells with a specific mutation (KRAS G12V). The study enrolls 30 people whose tumors carry this mutation a…

This study tests whether adding donor natural killer (NK) cells to standard chemotherapy can help prevent cancer from coming back after surgery for pancreatic or bile duct cancer. About 42 adults who had their tumor removed will receive either chemotherapy alone or chemotherapy p…

This study tests a wearable device that creates electric fields (TTFields) combined with chemotherapy for people with metastatic pancreatic cancer. The device is worn at home for at least 18 hours a day and aims to disrupt cancer cell division. The trial will check if the combina…

This study tests a more thorough surgery technique for pancreatic head cancer. The goal is to remove more tissue around the tumor to lower the chance of cancer returning. 90 adults with resectable cancer will be followed for 2 years to see if this approach improves survival and r…

This early-phase study tests whether adding a heat-based treatment (radiofrequency ablation) to chemotherapy is safe for people with advanced pancreatic cancer that hasn't spread to other organs. About 15 participants will receive the procedure through an endoscope guided by ultr…

This early-phase study tests a new drug called GV20-0251 in people with advanced solid tumors (like liver, lung, or skin cancer) that have stopped responding to standard therapies. The main goal is to check the drug's safety in a small group of 10 patients. It is not a cure, but …

This study tests whether a sequence of chemotherapy drugs plus two immunotherapy and anti-angiogenesis drugs works better than standard chemotherapy alone for people with advanced pancreatic cancer that cannot be removed by surgery. About 292 participants in China will be randoml…

This phase 2 trial is testing whether adding the drug anakinra (Kineret) to standard chemotherapy can improve outcomes for people with pancreatic cancer that can be surgically removed or is locally advanced. Anakinra is an anti-inflammatory drug typically used for rheumatoid arth…

This study tests a new drug called Spevatamig (PT886) in people with advanced stomach, pancreatic, or bile duct cancers that have spread or cannot be removed by surgery. The drug is a type of antibody that targets two proteins on cancer cells to help the immune system attack them…

This Phase 2 trial is testing whether adding an experimental immunotherapy (TQB2868) and a targeted drug (anlotinib) to standard chemotherapy can help people with pancreatic cancer that has spread. The study will enroll 80 adults who have not had prior treatment. Researchers will…

This phase 3 trial tests whether adding a surgical glue called N-butyl-2-cyanoacrylate to standard pancreatic surgery can prevent postoperative pancreatic fistula—a common and serious leak of digestive fluids. About 194 patients with soft pancreas tissue undergoing tumor removal …

This phase II trial tests a new approach for people with advanced pancreatic cancer that cannot be removed by surgery. Participants first receive standard chemotherapy, then an endoscopic procedure that uses heat to destroy tumor tissue (EUS-RFA), followed by the immunotherapy dr…

This study tests a new radioactive tracer called [18F]FPyQCP for PET scans to see if it can better detect several cancers, including colorectal, ovarian, gastric, breast, and pancreatic. About 71 adults with these cancers will receive the tracer and have a PET/CT scan. The goal i…

This study looks for new ways to diagnose pancreatic cancer, a disease that is often caught too late. Researchers will analyze fluid that is normally thrown away after a standard biopsy procedure. They hope to find proteins or other molecules that could lead to a simple blood tes…

This study compares two blood test methods for detecting circulating tumor cells (CTCs) that express a protein called Axl, which is linked to more aggressive cancer. The new technique, called EPIDROP, is being tested against the standard CellSearch method in patients with metasta…

This study tests a new PET/CT scan using a radioactive tracer called GEH300079 to detect peritoneal carcinomatosis—cancer that has spread to the lining of the abdomen—in people with colorectal, stomach, ovarian, or pancreatic cancer. About 175 adults with known or suspected sprea…

This study is testing a mixed meal test to better diagnose a specific type of diabetes (type 3c) that occurs in people with pancreatic cancer or chronic pancreatitis. Researchers will enroll 775 adults aged 30 to 84 who have new-onset diabetes and one of these pancreatic conditio…

This study aims to see if adding simple blood tests and symptom reviews to standard screening can catch pancreatic cancer earlier in people with a high genetic risk. Researchers will enroll 5,000 participants who have certain gene mutations linked to pancreatic cancer. The goal i…

This study tests whether a new imaging agent called [18F]FAPI-74 can find certain cancers as well as or better than the standard PET tracer. About 320 adults with one of 11 cancer types (including pancreatic, liver, ovarian, and lung cancers) will receive both tracers and have th…

This early-stage trial tests a radioactive imaging agent called RAD301 in 9 people: healthy volunteers and patients with pancreatic, lung, esophageal, cervical, endometrial, or ovarian cancer. The goal is to see how safe it is and how it travels through the body. If it works, it …

This study is testing a software called Lipidica that analyzes fats in the blood to help screen for pancreatic cancer. Researchers will compare results from people with pancreatic cancer to those at high risk (due to family history or genetic factors) to see if the software can t…

This study is testing whether adding an MRI scan to the usual CT scan helps doctors make better decisions about surgery for pancreatic cancer. About 200 patients who are initially thought to be candidates for surgery will be randomly assigned to get either a standard CT alone or …

This early-phase study is testing whether a special PET scan using a drug called PYLARIFY can better detect cancer that has spread in people with pancreatic cancer, liver cancer, or breast cancer. About 36 adults will receive the scan, and doctors will compare the results to stan…

This study is testing a new blood test that looks at fragments of DNA to find pancreatic neuroendocrine tumors early and tell them apart from other pancreatic tumors. Researchers will collect blood from 1,000 adults with different types of pancreatic tumors to see how accurate th…

This study tests a special PET probe called [68Ga]CBP8 to see if it can detect tissue damage caused by radiation therapy in people with lung or pancreatic cancer. About 72 participants will get a PET scan before and 3-6 months after radiation. The goal is to find early signs of r…

This study tests a new type of PET scan that uses a special tracer to light up a protein called FAP, found on pancreatic tumor tissue. The goal is to see if this scan can detect cancer spread that standard CT scans miss. Researchers will compare the new scan with CT in 60 adults …

This study is testing a new blood test called PANXEON that looks for tiny genetic particles (miRNAs) to detect pancreatic cancer early. Researchers will collect blood samples from 2,000 people—some with pancreatic cancer and some without—to see how accurate the test is. If it wor…

This study tests whether an MRI scan can detect tiny liver metastases that standard CT scans miss in people with pancreatic cancer. About 120 adults with newly diagnosed pancreatic cancer will get both a CT and an MRI before treatment. If MRI proves better at finding hidden cance…

This study tests an experimental MRI scan that uses a special contrast agent called hyperpolarized carbon-13 pyruvate to see how pancreatic tumors process nutrients. The goal is to find out if this scan can predict treatment response better than standard MRIs. About 70 adults wit…

This study tests whether a remote exercise and nutrition program is practical and acceptable for people with pancreatic cancer who are waiting for surgery. Participants will use a Fitbit, get nutrition advice, and do resistance training at home. The goal is to see if this 'prehab…

This pilot study is testing whether a structured program of exercise, nutrition counseling, and support—called prehabilitation—can help adults with pancreatic cancer get stronger before surgery. Twenty participants will follow the program while receiving chemotherapy before their…

This study is testing whether growing a patient's tumor cells in the lab (as 3D 'organoids') can help doctors pick the best drug for advanced cancers that have stopped responding to standard treatments. About 152 adults with colorectal or pancreatic cancer will have a biopsy to c…

This study looks at why people with pancreatic cancer often lose muscle and weight (cachexia). Researchers will collect blood, tissue, and imaging data from 500 patients to understand the biology and build an AI model that could warn doctors early. It is an observational study, s…

This study is tracking 20,000 people who have a family history of pancreatic cancer or carry genes that raise their risk. Researchers hope to find better ways to detect the disease early, when it's more treatable. Participants will be followed over time to see who develops pancre…

This study is testing a new technique called EXPEL to find biomarkers for pancreatic cancer. Researchers will analyze the fluid used to preserve biopsy samples from 200 patients with suspected pancreatic cancer. The goal is to identify proteins and other molecules that could help…

This study explores whether a special MRI technique called 3D-MRE can measure the stiffness of pancreatic tumors to help predict how the disease will progress. Researchers will enroll 200 adults with pancreatic cancer and compare imaging results with actual tumor hardness and tre…

This study looks at how obesity might help cause pancreatic cancer, especially in African American and non-Hispanic White people. Researchers will compare tumors and fat tissue from 125 adults to find differences that could lead to better treatments. The goal is to understand why…

This study looks at how pancreatic cancer cells get and use nutrients to grow. Researchers will give a special sugar to 16 patients during surgery to trace the cancer's energy use in the lab. The goal is to find weaknesses in the cancer's fuel system that could lead to new treatm…

This observational study tracks 80 people with advanced pancreatic cancer that has a specific genetic change called KRAS G12R. Participants receive one of three treatment plans: a MEK inhibitor combined with other drugs, with or without hydroxychloroquine or an EGFR inhibitor. Th…

This study collects blood and tumor samples from 100 people with pancreatic cancer who are about to receive standard chemotherapy before surgery. Researchers will use an artificial intelligence algorithm to analyze the tumor tissue and look for biomarkers that predict which treat…

This study is for people at high risk of pancreatic cancer, such as those with a strong family history or certain genetic conditions. Researchers will use MRI and endoscopic ultrasound to screen participants regularly and see which method works best. The goal is to detect cancer …

This study looks at tiny molecules called microRNA in the blood of people with advanced pancreatic cancer. Researchers want to see if these molecules can help diagnose the disease earlier, predict how it will progress, and show whether treatment is working. The study will follow …

This study tests a new screening program for people aged 50 to 85 who have recently developed diabetes and are at high risk for pancreatic cancer. Participants will receive repeated AI-enhanced CT scans and blood draws over time to see if these tools can spot cancer earlier than …

This study looks at whether a simple blood test can find tiny bits of tumor DNA (ctDNA and eccDNA) in people with pancreatic cancer that can be surgically removed. The goal is to see if these tests can predict if the cancer will come back early and help doctors monitor patients m…

This study is testing whether a simple rectal mucus sample can detect DNA changes linked to lung, pancreatic, bladder, and colorectal cancers. Researchers will collect samples from 450 adults using a special device and analyze them for genetic and epigenetic markers. The goal is …

This study enrolls 5,000 people at high risk for pancreatic cancer to donate blood, pancreatic juice, and medical images over 10 years. Researchers will use this information to develop and validate tests that can detect pancreatic cancer earlier, when it may be more treatable. Pa…

This study explores whether a special MRI technique called 3D magnetic resonance elastography (MRE) can accurately measure the stiffness of pancreatic tumors and surrounding scar tissue. Researchers will enroll 200 adults with pancreatic cancer to see if these stiffness measureme…

This study looks at tiny particles called exosomes, which carry proteins and genetic material between cells. Researchers will collect blood and tissue from 181 people with pancreatic cancer or noncancerous pancreatic disease to compare exosome activity. The goal is to understand …

This study looks at whether genetic information from tumors can help doctors choose better treatments for pancreatic cancer. About 200 adults with early or locally advanced pancreatic cancer will receive standard chemotherapy and provide blood, tissue, and fluid samples for genet…

This study looks at how pancreatic cancer changes over time in people receiving chemotherapy. Researchers take small tissue samples from the tumor at diagnosis and again after treatment to see if the cancer's genetic type has shifted. The goal is to better understand how the canc…

This study will follow 3,000 pancreatic cancer patients in China who are receiving irinotecan liposome II as part of their treatment. Researchers will collect data on side effects, survival, and how well the drug controls the cancer. The goal is to understand how this treatment w…

This study is testing whether a special type of ultrasound called multiparametric ultrasound (mpUS) can provide more detailed images of tissue than standard ultrasound. Researchers will compare mpUS results with regular tests in up to 85 people who are at high risk for pancreatic…

This study is developing a blood test that looks at tiny genetic particles called microRNAs to predict how well pancreatic cancer will respond to chemotherapy given before surgery. Researchers will collect blood samples from 200 patients with pancreatic cancer who are about to re…

This study is testing whether a blood test that looks for tumor DNA (ctDNA) can tell doctors within weeks if chemotherapy is shrinking a patient's pancreatic cancer. Currently, doctors wait about 8 weeks for a scan to see if treatment is working. The trial will enroll 50 people w…

This study follows 4,000 adults aged 30 and older who have at least one pancreatic cyst, a common finding on scans. Researchers will track changes over time using surveys and medical records to see which cysts turn into cancer. The goal is to better tell harmless cysts from dange…

This study looks at whether the spleen can be safely left in place during surgery for left-sided pancreatic cancer. Currently, the spleen is removed as a standard part of the operation to ensure any cancer in the surrounding fat is also taken out. The study will check how often c…

This study is looking for biological markers in the blood and tissue that can tell apart harmless pancreatic cysts (IPMN) from those that are likely to turn into pancreatic cancer. Researchers will follow 3,600 patients with IPMN across four Italian hospitals, collecting blood sa…